National Comprehensive Cancer Network Receives $1.5 Million Grant To Research Targeted Therapy In Bladder Cancer

NCCN (The National Comprehensive Cancer Network) has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive Cancer Center is the coordinating center for the study.

More: continued here

Filed under: Cancer on November 27th, 2008